Global Nuclide Drugs Market Research Report 2024(Status and Outlook)
Report Overview
Nuclide drugs, also known as radiopharmaceuticals, are a class of pharmaceuticals containing radioactive isotopes used in diagnostic and therapeutic procedures. These drugs play a crucial role in nuclear medicine, enabling the visualization and treatment of various medical conditions. Nuclide drugs are characterized by their ability to emit radiation that can be detected externally, aiding in the diagnosis and monitoring of diseases such as cancer, cardiovascular disorders, and neurological conditions.
The current market size for nuclide drugs in 2023 is estimated at approximately USD 5.6 billion. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.73% from 2024 to 2032. This growth can be attributed to several key factors driving the market forward.
One of the primary growth drivers for the nuclide drugs market is the increasing prevalence of cancer and other chronic diseases worldwide. As the global population ages and lifestyles change, the incidence of cancer and other diseases requiring nuclear medicine interventions is on the rise. This trend is expected to fuel the demand for nuclide drugs in the coming years.
Technological advancements in imaging techniques and radiopharmaceutical development are also contributing to market growth. Innovations in nuclear imaging modalities such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) have expanded the applications of nuclide drugs, making them more effective in diagnosing and treating various conditions.
Moreover, growing investments in healthcare infrastructure, particularly in emerging economies, are creating opportunities for market expansion. Improved access to nuclear medicine facilities and increasing awareness about the benefits of nuclide drugs are driving market growth in regions with previously limited healthcare resources.
In terms of market trends, personalized medicine is gaining traction in the nuclide drugs sector. Tailoring treatment plans based on individual patient characteristics and genetic profiles is becoming increasingly important in healthcare. Nuclide drugs play a significant role in personalized medicine by enabling targeted therapies and precise diagnostic imaging, leading to better patient outcomes.
Furthermore, there is a growing emphasis on theranostics, which combines diagnostic imaging and targeted therapy using radiopharmaceuticals. Theranostic approaches allow healthcare providers to diagnose conditions accurately and deliver personalized treatments, ultimately improving patient care and treatment efficacy.
Regionally, North America and Europe currently dominate the nuclide drugs market due to well-established healthcare systems, high adoption rates of advanced medical technologies, and significant investments in research and development. However, Asia-Pacific is expected to witness the fastest growth in the coming years, driven by increasing healthcare expenditure, rising awareness about nuclear medicine, and expanding access to advanced healthcare services.
Despite the promising growth prospects, the nuclide drugs market faces several challenges. Regulatory hurdles related to the approval and manufacturing of radiopharmaceuticals, reimbursement issues, and concerns about radiation exposure are key challenges that industry players need to address. Overcoming these obstacles will be crucial for sustaining market growth and ensuring the safe and effective use of nuclide drugs in clinical practice.
This report provides a deep insight into the global Nuclide Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Nuclide Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nuclide Drugs market in any manner.
Global Nuclide Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GE Healthcare
Cardinal Health
Curium Pharma
Lantheus Medical Imaging
Inc.
Eczac?baє? Monrol Nuclear Products
Novartis International AG
Siemens
China Isotope & Radiation
Yantai Dongcheng Pharmaceutical
Jubilant Life Sciences
Bracco
Market Segmentation (by Type)
Technetium-99
Iodine-123
Iodine-125
Iodine-131
Fluorine-18
Gallium-67
Others
Market Segmentation (by Application)
Therapeutic Use
Diagnostic Use
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Nuclide Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Nuclide drugs, also known as radiopharmaceuticals, are a class of pharmaceuticals containing radioactive isotopes used in diagnostic and therapeutic procedures. These drugs play a crucial role in nuclear medicine, enabling the visualization and treatment of various medical conditions. Nuclide drugs are characterized by their ability to emit radiation that can be detected externally, aiding in the diagnosis and monitoring of diseases such as cancer, cardiovascular disorders, and neurological conditions.
The current market size for nuclide drugs in 2023 is estimated at approximately USD 5.6 billion. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.73% from 2024 to 2032. This growth can be attributed to several key factors driving the market forward.
One of the primary growth drivers for the nuclide drugs market is the increasing prevalence of cancer and other chronic diseases worldwide. As the global population ages and lifestyles change, the incidence of cancer and other diseases requiring nuclear medicine interventions is on the rise. This trend is expected to fuel the demand for nuclide drugs in the coming years.
Technological advancements in imaging techniques and radiopharmaceutical development are also contributing to market growth. Innovations in nuclear imaging modalities such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) have expanded the applications of nuclide drugs, making them more effective in diagnosing and treating various conditions.
Moreover, growing investments in healthcare infrastructure, particularly in emerging economies, are creating opportunities for market expansion. Improved access to nuclear medicine facilities and increasing awareness about the benefits of nuclide drugs are driving market growth in regions with previously limited healthcare resources.
In terms of market trends, personalized medicine is gaining traction in the nuclide drugs sector. Tailoring treatment plans based on individual patient characteristics and genetic profiles is becoming increasingly important in healthcare. Nuclide drugs play a significant role in personalized medicine by enabling targeted therapies and precise diagnostic imaging, leading to better patient outcomes.
Furthermore, there is a growing emphasis on theranostics, which combines diagnostic imaging and targeted therapy using radiopharmaceuticals. Theranostic approaches allow healthcare providers to diagnose conditions accurately and deliver personalized treatments, ultimately improving patient care and treatment efficacy.
Regionally, North America and Europe currently dominate the nuclide drugs market due to well-established healthcare systems, high adoption rates of advanced medical technologies, and significant investments in research and development. However, Asia-Pacific is expected to witness the fastest growth in the coming years, driven by increasing healthcare expenditure, rising awareness about nuclear medicine, and expanding access to advanced healthcare services.
Despite the promising growth prospects, the nuclide drugs market faces several challenges. Regulatory hurdles related to the approval and manufacturing of radiopharmaceuticals, reimbursement issues, and concerns about radiation exposure are key challenges that industry players need to address. Overcoming these obstacles will be crucial for sustaining market growth and ensuring the safe and effective use of nuclide drugs in clinical practice.
This report provides a deep insight into the global Nuclide Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Nuclide Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nuclide Drugs market in any manner.
Global Nuclide Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GE Healthcare
Cardinal Health
Curium Pharma
Lantheus Medical Imaging
Inc.
Eczac?baє? Monrol Nuclear Products
Novartis International AG
Siemens
China Isotope & Radiation
Yantai Dongcheng Pharmaceutical
Jubilant Life Sciences
Bracco
Market Segmentation (by Type)
Technetium-99
Iodine-123
Iodine-125
Iodine-131
Fluorine-18
Gallium-67
Others
Market Segmentation (by Application)
Therapeutic Use
Diagnostic Use
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Nuclide Drugs Market
- Overview of the regional outlook of the Nuclide Drugs Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Nuclide Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Nuclide Drugs
1.2 Key Market Segments
1.2.1 Nuclide Drugs Segment by Type
1.2.2 Nuclide Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NUCLIDE DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Nuclide Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Nuclide Drugs Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
2.4 Macroeconomic Analysis
3 NUCLIDE DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Nuclide Drugs Sales by Manufacturers (2019-2024)
3.2 Global Nuclide Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Nuclide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Nuclide Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Nuclide Drugs Sales Sites, Area Served, Product Type
3.6 Nuclide Drugs Market Competitive Situation and Trends
3.6.1 Nuclide Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Nuclide Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NUCLIDE DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Nuclide Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NUCLIDE DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NUCLIDE DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Nuclide Drugs Sales Market Share by Type (2019-2024)
6.3 Global Nuclide Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Nuclide Drugs Price by Type (2019-2024)
7 NUCLIDE DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Nuclide Drugs Market Sales by Application (2019-2024)
7.3 Global Nuclide Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Nuclide Drugs Sales Growth Rate by Application (2019-2024)
8 NUCLIDE DRUGS MARKET SALES BY REGION
8.1 Global Nuclide Drugs Sales by Region
8.1.1 Global Nuclide Drugs Sales by Region
8.1.2 Global Nuclide Drugs Sales Market Share by Region
8.2 Global Nuclide Drugs Market Size by Region
8.2.1 Global Nuclide Drugs Market Size by Region
8.2.2 Global Nuclide Drugs Market Size Market Share by Region
8.3 North America
8.3.1 North America Nuclide Drugs Sales by Country
8.3.2 North America Nuclide Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Nuclide Drugs Sales by Country
8.4.2 Europe Nuclide Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Russia Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Nuclide Drugs Sales by Region
8.5.2 China
8.5.3 Japan
8.5.4 South Korea
8.5.5 India
8.5.6 Southeast Asia
8.6 Asia Pacific
8.6.1 Asia Pacific Nuclide Drugs Market Size by Region
8.6.2 Asia Pacific Nuclide Drugs Market Size by Region
8.6.3 China
8.6.4 Japan
8.6.5 South Korea
8.6.6 India
8.6.7 Southeast Asia
8.7 South America
8.7.1 South America Nuclide Drugs Sales by Country
8.7.2 South America Nuclide Drugs Market Size by Country
8.7.3 Brazil
8.7.4 Argentina
8.7.5 Columbia
8.8 Middle East and Africa
8.8.1 Middle East and Africa Nuclide Drugs Sales by Region
8.8.2 Middle East and Africa Nuclide Drugs Market Size by Region
8.8.3 Saudi Arabia
8.8.4 UAE
8.8.5 Egypt
8.8.6 Nigeria
8.8.7 South Africa
9 NUCLIDE DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Nuclide Drugs by Region (2019-2024)
9.2 Global Nuclide Drugs Revenue Market Share by Region (2019-2024)
9.3 Global Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Nuclide Drugs Production
9.4.1 North America Nuclide Drugs Production Growth Rate (2019-2024)
9.4.2 North America Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Nuclide Drugs Production
9.5.1 Europe Nuclide Drugs Production Growth Rate (2019-2024)
9.5.2 Europe Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Nuclide Drugs Production (2019-2024)
9.6.1 Japan Nuclide Drugs Production Growth Rate (2019-2024)
9.6.2 Japan Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Nuclide Drugs Production (2019-2024)
9.7.1 China Nuclide Drugs Production Growth Rate (2019-2024)
9.7.2 China Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 GE Healthcare
10.1.1 GE Healthcare Nuclide Drugs Basic Information
10.1.2 GE Healthcare Nuclide Drugs Product Overview
10.1.3 GE Healthcare Nuclide Drugs Product Market Performance
10.1.4 GE Healthcare Business Overview
10.1.5 GE Healthcare Nuclide Drugs SWOT Analysis
10.1.6 GE Healthcare Recent Developments
10.2 Cardinal Health
10.2.1 Cardinal Health Nuclide Drugs Basic Information
10.2.2 Cardinal Health Nuclide Drugs Product Overview
10.2.3 Cardinal Health Nuclide Drugs Product Market Performance
10.2.4 Cardinal Health Business Overview
10.2.5 Cardinal Health Nuclide Drugs SWOT Analysis
10.2.6 Cardinal Health Recent Developments
10.3 Curium Pharma
10.3.1 Curium Pharma Nuclide Drugs Basic Information
10.3.2 Curium Pharma Nuclide Drugs Product Overview
10.3.3 Curium Pharma Nuclide Drugs Product Market Performance
10.3.4 Curium Pharma Nuclide Drugs SWOT Analysis
10.3.5 Curium Pharma Business Overview
10.3.6 Curium Pharma Recent Developments
10.4 Lantheus Medical Imaging
10.4.1 Lantheus Medical Imaging Nuclide Drugs Basic Information
10.4.2 Lantheus Medical Imaging Nuclide Drugs Product Overview
10.4.3 Lantheus Medical Imaging Nuclide Drugs Product Market Performance
10.4.4 Lantheus Medical Imaging Business Overview
10.4.5 Lantheus Medical Imaging Recent Developments
10.5 Inc.
10.5.1 Inc. Nuclide Drugs Basic Information
10.5.2 Inc. Nuclide Drugs Product Overview
10.5.3 Inc. Nuclide Drugs Product Market Performance
10.5.4 Inc. Business Overview
10.5.5 Inc. Recent Developments
10.6 Eczac?baє? Monrol Nuclear Products
10.6.1 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Basic Information
10.6.2 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Product Overview
10.6.3 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Product Market Performance
10.6.4 Eczac?baє? Monrol Nuclear Products Business Overview
10.6.5 Eczac?baє? Monrol Nuclear Products Recent Developments
10.7 Novartis International AG
10.7.1 Novartis International AG Nuclide Drugs Basic Information
10.7.2 Novartis International AG Nuclide Drugs Product Overview
10.7.3 Novartis International AG Nuclide Drugs Product Market Performance
10.7.4 Novartis International AG Business Overview
10.7.5 Novartis International AG Recent Developments
10.8 Siemens
10.8.1 Siemens Nuclide Drugs Basic Information
10.8.2 Siemens Nuclide Drugs Product Overview
10.8.3 Siemens Nuclide Drugs Product Market Performance
10.8.4 Siemens Business Overview
10.8.5 Siemens Recent Developments
10.9 China Isotope and Radiation
10.9.1 China Isotope and Radiation Nuclide Drugs Basic Information
10.9.2 China Isotope and Radiation Nuclide Drugs Product Overview
10.9.3 China Isotope and Radiation Nuclide Drugs Product Market Performance
10.9.4 China Isotope and Radiation Business Overview
10.9.5 China Isotope and Radiation Recent Developments
10.10 Yantai Dongcheng Pharmaceutical
10.10.1 Yantai Dongcheng Pharmaceutical Nuclide Drugs Basic Information
10.10.2 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Overview
10.10.3 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Market Performance
10.10.4 Yantai Dongcheng Pharmaceutical Business Overview
10.10.5 Yantai Dongcheng Pharmaceutical Recent Developments
10.11 Jubilant Life Sciences
10.11.1 Jubilant Life Sciences Nuclide Drugs Basic Information
10.11.2 Jubilant Life Sciences Nuclide Drugs Product Overview
10.11.3 Jubilant Life Sciences Nuclide Drugs Product Market Performance
10.11.4 Jubilant Life Sciences Business Overview
10.11.5 Jubilant Life Sciences Recent Developments
10.12 Bracco
10.12.1 Bracco Nuclide Drugs Basic Information
10.12.2 Bracco Nuclide Drugs Product Overview
10.12.3 Bracco Nuclide Drugs Product Market Performance
10.12.4 Bracco Business Overview
10.12.5 Bracco Recent Developments
11 NUCLIDE DRUGS MARKET FORECAST BY REGION
11.1 Global Nuclide Drugs Market Size Forecast
11.2 Global Nuclide Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Nuclide Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Nuclide Drugs Market Size Forecast by Region
11.2.4 South America Nuclide Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Nuclide Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Nuclide Drugs Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Nuclide Drugs by Type (2025-2032)
12.1.2 Global Nuclide Drugs Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Nuclide Drugs by Type (2025-2032)
12.2 Global Nuclide Drugs Market Forecast by Application (2025-2032)
12.2.1 Global Nuclide Drugs Sales (K MT) Forecast by Application
12.2.2 Global Nuclide Drugs Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Nuclide Drugs
1.2 Key Market Segments
1.2.1 Nuclide Drugs Segment by Type
1.2.2 Nuclide Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NUCLIDE DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Nuclide Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Nuclide Drugs Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
2.4 Macroeconomic Analysis
3 NUCLIDE DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Nuclide Drugs Sales by Manufacturers (2019-2024)
3.2 Global Nuclide Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Nuclide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Nuclide Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Nuclide Drugs Sales Sites, Area Served, Product Type
3.6 Nuclide Drugs Market Competitive Situation and Trends
3.6.1 Nuclide Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Nuclide Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NUCLIDE DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Nuclide Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NUCLIDE DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NUCLIDE DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Nuclide Drugs Sales Market Share by Type (2019-2024)
6.3 Global Nuclide Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Nuclide Drugs Price by Type (2019-2024)
7 NUCLIDE DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Nuclide Drugs Market Sales by Application (2019-2024)
7.3 Global Nuclide Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Nuclide Drugs Sales Growth Rate by Application (2019-2024)
8 NUCLIDE DRUGS MARKET SALES BY REGION
8.1 Global Nuclide Drugs Sales by Region
8.1.1 Global Nuclide Drugs Sales by Region
8.1.2 Global Nuclide Drugs Sales Market Share by Region
8.2 Global Nuclide Drugs Market Size by Region
8.2.1 Global Nuclide Drugs Market Size by Region
8.2.2 Global Nuclide Drugs Market Size Market Share by Region
8.3 North America
8.3.1 North America Nuclide Drugs Sales by Country
8.3.2 North America Nuclide Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Nuclide Drugs Sales by Country
8.4.2 Europe Nuclide Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Russia Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Nuclide Drugs Sales by Region
8.5.2 China
8.5.3 Japan
8.5.4 South Korea
8.5.5 India
8.5.6 Southeast Asia
8.6 Asia Pacific
8.6.1 Asia Pacific Nuclide Drugs Market Size by Region
8.6.2 Asia Pacific Nuclide Drugs Market Size by Region
8.6.3 China
8.6.4 Japan
8.6.5 South Korea
8.6.6 India
8.6.7 Southeast Asia
8.7 South America
8.7.1 South America Nuclide Drugs Sales by Country
8.7.2 South America Nuclide Drugs Market Size by Country
8.7.3 Brazil
8.7.4 Argentina
8.7.5 Columbia
8.8 Middle East and Africa
8.8.1 Middle East and Africa Nuclide Drugs Sales by Region
8.8.2 Middle East and Africa Nuclide Drugs Market Size by Region
8.8.3 Saudi Arabia
8.8.4 UAE
8.8.5 Egypt
8.8.6 Nigeria
8.8.7 South Africa
9 NUCLIDE DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Nuclide Drugs by Region (2019-2024)
9.2 Global Nuclide Drugs Revenue Market Share by Region (2019-2024)
9.3 Global Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Nuclide Drugs Production
9.4.1 North America Nuclide Drugs Production Growth Rate (2019-2024)
9.4.2 North America Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Nuclide Drugs Production
9.5.1 Europe Nuclide Drugs Production Growth Rate (2019-2024)
9.5.2 Europe Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Nuclide Drugs Production (2019-2024)
9.6.1 Japan Nuclide Drugs Production Growth Rate (2019-2024)
9.6.2 Japan Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Nuclide Drugs Production (2019-2024)
9.7.1 China Nuclide Drugs Production Growth Rate (2019-2024)
9.7.2 China Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 GE Healthcare
10.1.1 GE Healthcare Nuclide Drugs Basic Information
10.1.2 GE Healthcare Nuclide Drugs Product Overview
10.1.3 GE Healthcare Nuclide Drugs Product Market Performance
10.1.4 GE Healthcare Business Overview
10.1.5 GE Healthcare Nuclide Drugs SWOT Analysis
10.1.6 GE Healthcare Recent Developments
10.2 Cardinal Health
10.2.1 Cardinal Health Nuclide Drugs Basic Information
10.2.2 Cardinal Health Nuclide Drugs Product Overview
10.2.3 Cardinal Health Nuclide Drugs Product Market Performance
10.2.4 Cardinal Health Business Overview
10.2.5 Cardinal Health Nuclide Drugs SWOT Analysis
10.2.6 Cardinal Health Recent Developments
10.3 Curium Pharma
10.3.1 Curium Pharma Nuclide Drugs Basic Information
10.3.2 Curium Pharma Nuclide Drugs Product Overview
10.3.3 Curium Pharma Nuclide Drugs Product Market Performance
10.3.4 Curium Pharma Nuclide Drugs SWOT Analysis
10.3.5 Curium Pharma Business Overview
10.3.6 Curium Pharma Recent Developments
10.4 Lantheus Medical Imaging
10.4.1 Lantheus Medical Imaging Nuclide Drugs Basic Information
10.4.2 Lantheus Medical Imaging Nuclide Drugs Product Overview
10.4.3 Lantheus Medical Imaging Nuclide Drugs Product Market Performance
10.4.4 Lantheus Medical Imaging Business Overview
10.4.5 Lantheus Medical Imaging Recent Developments
10.5 Inc.
10.5.1 Inc. Nuclide Drugs Basic Information
10.5.2 Inc. Nuclide Drugs Product Overview
10.5.3 Inc. Nuclide Drugs Product Market Performance
10.5.4 Inc. Business Overview
10.5.5 Inc. Recent Developments
10.6 Eczac?baє? Monrol Nuclear Products
10.6.1 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Basic Information
10.6.2 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Product Overview
10.6.3 Eczac?baє? Monrol Nuclear Products Nuclide Drugs Product Market Performance
10.6.4 Eczac?baє? Monrol Nuclear Products Business Overview
10.6.5 Eczac?baє? Monrol Nuclear Products Recent Developments
10.7 Novartis International AG
10.7.1 Novartis International AG Nuclide Drugs Basic Information
10.7.2 Novartis International AG Nuclide Drugs Product Overview
10.7.3 Novartis International AG Nuclide Drugs Product Market Performance
10.7.4 Novartis International AG Business Overview
10.7.5 Novartis International AG Recent Developments
10.8 Siemens
10.8.1 Siemens Nuclide Drugs Basic Information
10.8.2 Siemens Nuclide Drugs Product Overview
10.8.3 Siemens Nuclide Drugs Product Market Performance
10.8.4 Siemens Business Overview
10.8.5 Siemens Recent Developments
10.9 China Isotope and Radiation
10.9.1 China Isotope and Radiation Nuclide Drugs Basic Information
10.9.2 China Isotope and Radiation Nuclide Drugs Product Overview
10.9.3 China Isotope and Radiation Nuclide Drugs Product Market Performance
10.9.4 China Isotope and Radiation Business Overview
10.9.5 China Isotope and Radiation Recent Developments
10.10 Yantai Dongcheng Pharmaceutical
10.10.1 Yantai Dongcheng Pharmaceutical Nuclide Drugs Basic Information
10.10.2 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Overview
10.10.3 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Market Performance
10.10.4 Yantai Dongcheng Pharmaceutical Business Overview
10.10.5 Yantai Dongcheng Pharmaceutical Recent Developments
10.11 Jubilant Life Sciences
10.11.1 Jubilant Life Sciences Nuclide Drugs Basic Information
10.11.2 Jubilant Life Sciences Nuclide Drugs Product Overview
10.11.3 Jubilant Life Sciences Nuclide Drugs Product Market Performance
10.11.4 Jubilant Life Sciences Business Overview
10.11.5 Jubilant Life Sciences Recent Developments
10.12 Bracco
10.12.1 Bracco Nuclide Drugs Basic Information
10.12.2 Bracco Nuclide Drugs Product Overview
10.12.3 Bracco Nuclide Drugs Product Market Performance
10.12.4 Bracco Business Overview
10.12.5 Bracco Recent Developments
11 NUCLIDE DRUGS MARKET FORECAST BY REGION
11.1 Global Nuclide Drugs Market Size Forecast
11.2 Global Nuclide Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Nuclide Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Nuclide Drugs Market Size Forecast by Region
11.2.4 South America Nuclide Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Nuclide Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Nuclide Drugs Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Nuclide Drugs by Type (2025-2032)
12.1.2 Global Nuclide Drugs Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Nuclide Drugs by Type (2025-2032)
12.2 Global Nuclide Drugs Market Forecast by Application (2025-2032)
12.2.1 Global Nuclide Drugs Sales (K MT) Forecast by Application
12.2.2 Global Nuclide Drugs Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
